Novel treatments for castration-resistant prostate cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Sternberg, Cora N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCIUM; CUSTIRSEN; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN A RECEPTOR ANTAGONIST; IPILIMUMAB; IPILUMIMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF; PROVENGE; SATRAPLATIN; SUNITINIB; TASQUINIMOD; UNCLASSIFIED DRUG; VACCINIA VACCINE; VITAMIN D; ZIBOTENTAN; ZOLEDRONIC ACID;

ARTICLE; BONE DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; VITAMIN SUPPLEMENTATION;

CARCINOMA; CLINICAL TRIALS, PHASE III AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; THERAPIES, INVESTIGATIONAL; TREATMENT FAILURE;

EID: 80053273666     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70165-4     Document Type: Article

References (23)

1. HI Scher, S Halabi, I Tannock et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2) J Clin Oncol 26 7 2008 1148 1159
2. JS de Bono, HI Scher, RB Montgomery et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 19 2008 6302 6309
3. IF Tannock, D Osoba, MR Stochler et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A Canadian randomized trial with palliative end-points J Clin Oncol 14 6 1996 1756 1764 (Pubitemid 26185452)
4. PW Kantoff, S Halabi, M Conaway et al. Hydrocortisone with or without mitoxantrone in men with with hormone refractory prostate cancer: results of Cancer and Leukemia Group B 9182 study J Clin Oncol 17 1999 2506 2513 (Pubitemid 29368252)
5. IF Tannock, R de Wit, WR Berry et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer NEnglJMed 351 15 2004 1502 1512 (Pubitemid 39315317)
6. DP Petrylak, CM Tangen, MH Hussain et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520 (Pubitemid 39315318)
7. DR Berthold, GR Pond, F Soban, R de Wit, M Eisenberger, IF Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 2008 242 245
8. J de Bono N Engl J Med 2011 in press.
9. PW Kantoff, CS Higano, ND Shore et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl JMed 363 5 2010 411 422
10. JS de Bono, S Oudard, M Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 9747 2010 1147 1154
11. PW Kantoff, TJ Schuetz, BA Blumenstein et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
12. WK Kelly et al. J Clin Oncol 28 2010 18s (abstract LBA4511).
13. ND James, A Caty, H Payne et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone métastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial BJU Int 106 7 2010 966 973
14. KN Chi et al. J Clin Oncol 28 27 2010 4247 4254
15. CN Sternberg, DP Petrylak, O Sartor et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 32 2009 5431 5438
16. EJ Small, PF Schellhammer, CS Higano et al. Placebo-controlled phase III trial of immunologie therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094 (Pubitemid 46638945)
17. CS Higano, PF Schellhammer, EJ Small et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
18. F Saad, DM Gleason, R Murray et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 ll 2004 879 882 (Pubitemid 38807610)
19. K Fizazi, M Carducci, M Smith et al. Denosumab versus zoledronic acid for treatment of bone métastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 9768 2011 813 822
20. EY Yu, G Wilding, E Posadas et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 23 2009 7421 7428
21. EY Yu, C Massard, ME Gross et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer Urology 77 5 2011 1166 1171
22. JT Isaacs, R Pili, DZ Qian et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer Prostate 66 16 2006 1768 1778 (Pubitemid 44893902)
23. R Pili, M Haggman, WM Stadler et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC) Proc Annu Meet Am Soc Clin Oncol 28 2010 15s